Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with SarcomaHOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (
NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor microenvironment (TME) ex vivo to evaluate the effect of SON-1010 (IL-12-FHAB) in soft tissue sarcoma. The study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers.
Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug DevelopmentHOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Spanios, a leader in human-derived organoid model systems, is pleased to announce a strategic partnership with White Lion Capital LLC. This collaboration empowers biotech and pharma companies to leverage Spanios’ patient-derived tumoroid (tumor organoid) models for robust preclinical validation while accessing innovative funding from White Lion Capital LLC to advance their clinical development.
